CARL ZEISS MEDITEC invests in expansion of sales at Spain.

-A single supplier for a portfolio of solutions of Ophthalmology

Spain, September 2011.- Carl Zeiss Meditec AG medical technology provider announced its intention to acquire business of intraocular lenses (IOLs) and ophthalmic devices (OVDs) viscoelastic of IMEX to strengthen its salesservice and distribution network in Spain. This is the objective of the acquisition of assets agreement signed by both parties this afternoon in Vienna, Austria. IMEX has been, until now, partner Carl Zeiss Meditec exclusively for their business IOL and OVD in the Iberian Peninsula. The closure of the operation is expected by the end of 2011.

Carl Zeiss Meditec growth strategy is to provide comprehensive solutions of products and excellent services to its clients. Merging the sales forces of IMEX and Carl Zeiss Meditec, Spain, will allow us to offer our customers Iberian, diagnosis and surgery equipment, as well as IOLs and OVDs for ophthalmologic surgical procedures from a single provider ” explains Dr. Ludwin Mon, President and CEO of Carl Zeiss Meditec AG. The Union of these forces, Carl Zeiss Meditec may establish a strong and highly competitive team of ophthalmic experts in the market. Carl Zeiss Meditec will keep the outstanding level of service and support that characterizes both companies. Dr. Mon continues: this approach will result in a reduced complexity for customers, since they may deal with a single partner ”. In addition, Carl Zeiss Meditec expected to improve their business performance through the replacement of indirect sales channels.

Spain has always been an important market for Carl Zeiss Meditec, especially in the business of ophthalmological surgery, which in recent years has been successfully developed and expanded by IMEX in Portugal. With this acquisition, Carl Zeiss Meditec strengthens its business, especially in Spain, by systematically investing in its sales and services organisation. This step will increase our penetration in the market and will support our future growth ” concludes Dr. Ludwin Mon.

About Carl Zeiss

Carl Zeiss Meditec AG (ISIN: DE0005313704), is listed on TecDAX of the stock exchange German, is one of the leading suppliers of medical technology in the world. The company provides innovative technologies and solutions oriented applications designed to help physicians improve the quality of life for their patients. Offers complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and supplies. The company creates innovative display solutions in the field of microsurgery.
Carl Zeiss Meditec medical technology offering is completed with promising future as a intraoperativa radiation therapy technologies. In fiscal year 2009 / 2010 (September 30), nearly 2,200 employees in the company generated an income of 676 million euros.

Carl Zeiss Meditec headquarters are in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50% of employees are based in us, Japan, Spain and France. 35% Of the shares of Carl Zeiss Meditec listed. The remaining 65 per cent are owned by Carl Zeiss AG, one of the leading groups in the optical and opto-electronics industry worldwide.

Carl Zeiss offers innovative solutions for future markets medical solutions-oriented and design products, industrial solutions, vision care and research. In fiscal year 2009 / 2010, the group generated revenue of around EUR 2,980 million. Fiscal year 2010/2011en forward, the manufacturer of eye lens Carl Zeiss Vision must be integrated as a stand-alone business group (with revenues of around 880 million in fiscal year 2009 / 2010). In this way, the Carl Zeiss Group employs a workforce of 24,000 professionals worldwide, of which more than 10,000 have their base in Germany. Carl Zeiss, AG Oberckochen, is owned by the Carl Zeiss Foundation.